Natco Pharma Invests $14M in eGenesis for Organ Transplant Tech

Natco Pharma Limited announced an investment of US$ 14 million in eGenesis, Inc. through its wholly owned subsidiaries, NATCO Pharma (Canada) Inc. (US$ 9.5 million) and NATCO Pharma South Africa Proprietary Limited (US$ 4.5 million) via convertible promissory notes. This follows a previous investment of US$ 8 million in 2024, bringing the total investment to US$ 22 million. eGenesis is a biotechnology company focused on developing transplantable organs using genome engineering to address the global organ shortage. Their technology aims to overcome cross-species incompatibilities and viral risks. eGenesis has achieved milestones like the world's first porcine kidney transplant in a living patient, authorized by the FDA. The investment supports Natco's strategy in new-age therapeutic programs addressing critical unmet medical needs.